Payment overview · 2025
General Payments
$18.38
1 reported records · 1 companies
Healthcare provider profile · identity verified
Sunil Malhotra, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTHAVEN, MS · NPI 1841369907
Verified facts
What the public records show
CMS Open Payments records show Sunil Malhotra, MD received $18.38 in general payments during 2025 across 1 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Xifaxan.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.38 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $18.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 441 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 392 | 91 |
| Furosemide | Furosemide | 325 | 67 |
| Gabapentin | Gabapentin | 222 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 215 | 56 |
| Metformin Hcl | Metformin Hcl | 208 | 45 |
| Carvedilol | Carvedilol | 207 | 35 |
| Trazodone Hcl | Trazodone Hcl | 206 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 204 | 33 |
| Potassium Chloride | Potassium Chloride | 204 | 44 |
| Eliquis | Apixaban | 197 | 35 |
| Mirtazapine | Mirtazapine | 192 | 24 |
| Sertraline Hcl | Sertraline Hcl | 188 | 23 |
| Losartan Potassium | Losartan Potassium | 175 | 54 |
| Omeprazole | Omeprazole | 174 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 159 | 41 |
| Lisinopril | Lisinopril | 139 | 36 |
| Donepezil Hcl | Donepezil Hcl | 132 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 34 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 124 | 42 |
| Famotidine | Famotidine | 111 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 107 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 23 |
| Memantine Hcl | Memantine Hcl | 101 | 14 |
| Montelukast Sodium | Montelukast Sodium | 96 | 16 |
| Prednisone | Prednisone | 96 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 25 |
| Levetiracetam | Levetiracetam | 71 | suppressed |
| Simvastatin | Simvastatin | 71 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 50 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 16 |
| Xarelto | Rivaroxaban | 64 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 12 |
| Spironolactone | Spironolactone | 56 | 13 |
| Entresto | Sacubitril/Valsartan | 55 | suppressed |
| Methylprednisolone | Methylprednisolone | 55 | 36 |
| Allopurinol | Allopurinol | 53 | 12 |
| Cefuroxime | Cefuroxime Axetil | 53 | 40 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 50 | 15 |
| Azithromycin | Azithromycin | 47 | 37 |
| Ezetimibe | Ezetimibe | 47 | 12 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 45 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | suppressed |
| Novolog Flexpen | Insulin Aspart | 44 | 15 |
| Risperidone | Risperidone | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | 20 |
| Cephalexin | Cephalexin | 41 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Jardiance | Empagliflozin | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 39 | 25 |
| Meclizine Hcl | Meclizine Hcl | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 18 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 24 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 26 | 15 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Ingrezza | Valbenazine Tosylate | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 15 |
| Glimepiride | Glimepiride | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Xifaxan | Rifaximin | 19 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18.38 · 1 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Xifaxan play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Salix Pharmaceuticals, a division of Bausch Health US, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error